Literature DB >> 25573776

Identification of diabetes-related dementia: Longitudinal perfusion SPECT and amyloid PET studies.

Raita Fukasawa1, Haruo Hanyu2, Soichiro Shimizu1, Hidekazu Kanetaka1, Hirofumi Sakurai1, Kenji Ishii3.   

Abstract

AIMS: We attempted to identify a dementia subgroup with characteristics associated with diabetes mellitus (DM)-related metabolic abnormalities, referred to as diabetes-related dementia, using longitudinal single photon emission computed tomography (SPECT) and Pittsburgh compound-B (PiB) positron emission tomography (PET).
METHODS: We classified 175 patients with clinically diagnosed Alzheimer disease (AD) and DM into 4 subgroups based on brain imaging in a 2013 study. Among them, we investigated follow-up SPECT studies in 29 patients of an AD group showing decreased regional cerebral blood flow (rCBF) of the parietotemporal lobe on initial SPECT and 18 patients of a diabetes-related dementia group showing neither decreased rCBF of the parietotemporal lobe nor cerebrovascular disease, which is strongly associated with DM-related factors. Eleven of them underwent PiB PET.
RESULTS: Follow-up SPECT showed more profound rCBF reduction in the parietotemporal lobe and other areas of the AD group, whereas follow-up SPECT showed an rCBF reduction in small areas of the frontotemporal and limbic lobes of the diabetes-related dementia group. Six of 9 patients with diabetes-related dementia were negative or equivocal for PiB binding.
CONCLUSION: A subset of a dementia subgroup with characteristics predominantly associated with DM-related factors may underlie a pathophysiology different from AD, although these patients were clinically diagnosed as having AD. The identification of diabetes-related dementia may be necessary for considering an appropriate therapy and prevention in clinical practice.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Dementia; Diabetes mellitus; Diabetes-related dementia; Pittsburgh compound-B PET; Single photon emission CT

Mesh:

Year:  2014        PMID: 25573776     DOI: 10.1016/j.jns.2014.12.023

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Diabetes-Specific Dementia: A Structured Literature Review of Cognitive Assessment Methods.

Authors:  Kelli L Faaitiiti; Daniel C Jupiter
Journal:  J Foot Ankle Surg       Date:  2021-11-14       Impact factor: 1.286

Review 2.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

3.  Cerebrospinal fluid analysis in individuals with diabetes-related dementia.

Authors:  Hidekazu Kanetaka; Raita Fukasawa; Soichiro Shimizu; Naohito Takenoshita; Haruo Hanyu
Journal:  eNeurologicalSci       Date:  2017-06-13

4.  Decreased Muscle Strength and Quality in Diabetes-Related Dementia.

Authors:  Akito Tsugawa; Yusuke Ogawa; Naoto Takenoshita; Yoshitsugu Kaneko; Hirokuni Hatanaka; Eriko Jaime; Raita Fukasawa; Haruo Hanyu
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2017-12-22

5.  Serine Phosphorylation of IRS1 Correlates with Aβ-Unrelated Memory Deficits and Elevation in Aβ Level Prior to the Onset of Memory Decline in AD.

Authors:  Wei Wang; Daisuke Tanokashira; Yusuke Fukui; Megumi Maruyama; Chiemi Kuroiwa; Takashi Saito; Takaomi C Saido; Akiko Taguchi
Journal:  Nutrients       Date:  2019-08-17       Impact factor: 5.717

6.  p66Shc Signaling Mediates Diabetes-Related Cognitive Decline.

Authors:  Yohei Minami; Noriyuki Sonoda; Eiichi Hayashida; Hiroaki Makimura; Makoto Ide; Noriko Ikeda; Masahiro Ohgidani; Takahiro A Kato; Yoshihiro Seki; Yasutaka Maeda; Shigenobu Kanba; Ryoichi Takayanagi; Yoshihiro Ogawa; Toyoshi Inoguchi
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.